These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34077739)

  • 1. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib.
    Dent P; Booth L; Poklepovic A; Von Hoff D; Martinez J; Zhou Y; Hancock JF
    Biochem Pharmacol; 2021 Aug; 190():114642. PubMed ID: 34077739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
    Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
    Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.
    Dent P; Booth L; Poklepovic A; Martinez J; Hoff DV; Hancock JF
    J Cell Physiol; 2020 Nov; 235(11):7889-7899. PubMed ID: 31912905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells.
    Booth L; Poklepovic A; Hancock JF; Dent P
    Anticancer Drugs; 2023 Oct; 34(9):1025-1034. PubMed ID: 37703296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
    Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
    J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
    Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
    Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFR
    Xu J; Zhu GY; Cao D; Pan H; Li YW
    Biomed Pharmacother; 2019 Jul; 115():108860. PubMed ID: 31055235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
    He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
    Elife; 2021 Aug; 10():. PubMed ID: 34463254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins.
    Booth L; West C; Moore RP; Von Hoff D; Dent P
    Front Oncol; 2021; 11():711043. PubMed ID: 34490108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line.
    Verusingam ND; Chen YC; Lin HF; Liu CY; Lee MC; Lu KH; Cheong SK; Han-Kiat Ong A; Chiou SH; Wang ML
    J Chin Med Assoc; 2021 Mar; 84(3):248-254. PubMed ID: 33009209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC).
    Bracht JWP; Karachaliou N; Berenguer J; Pedraz-Valdunciel C; Filipska M; Codony-Servat C; Codony-Servat J; Rosell R
    Int J Biol Sci; 2019; 15(12):2607-2614. PubMed ID: 31754333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
    Chen Z; Yu D; Owonikoko TK; Ramalingam SS; Sun SY
    Oncogene; 2021 Dec; 40(49):6653-6665. PubMed ID: 34635799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
    Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation.
    Oku Y; Nishiya N; Sugiyama S; Sato H; Uehara Y
    Anticancer Res; 2018 Jun; 38(6):3471-3476. PubMed ID: 29848699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
    Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
    J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Molecular Target in
    Takano N; Seike M; Sugano T; Matsuda K; Hisakane K; Yoshikawa A; Nakamichi S; Noro R; Gemma A
    Anticancer Res; 2022 Feb; 42(2):709-722. PubMed ID: 35093869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin signalling regulates YAP and TAZ to control skin homeostasis.
    Elbediwy A; Vincent-Mistiaen ZI; Spencer-Dene B; Stone RK; Boeing S; Wculek SK; Cordero J; Tan EH; Ridgway R; Brunton VG; Sahai E; Gerhardt H; Behrens A; Malanchi I; Sansom OJ; Thompson BJ
    Development; 2016 May; 143(10):1674-87. PubMed ID: 26989177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.